Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BRTX Stock Forecast 2026-2027
$0.39
Current Price
$9.96M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BRTX Price Targets
+3,736.3%
To High Target of $15.00
+1,946.0%
To Median Target of $8.00
+155.8%
To Low Target of $1.00
BRTX Price Momentum
0.0%
1 Week Change
+105.3%
1 Month Change
-75.9%
1 Year Change
-66.7%
Year-to-Date Change
-79.3%
From 52W High of $1.89
+145.4%
From 52W Low of $0.16
📊 TOP ANALYST CALLS
Did BRTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BioRestorative is one of their latest high-conviction picks.
Latest BRTX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, BRTX has a bullish consensus with a median price target of $8.00 (ranging from $1.00 to $15.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $0.39, the median forecast implies a 1,946.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BRTX Analyst Ratings
2
Buy
0
Hold
0
Sell
BRTX Price Target Range
Low
$1.00
Average
$8.00
High
$15.00
Current: $0.39
Latest BRTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BRTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 14, 2024 | Roth MKM | Jonathan Aschoff | Buy | Maintains | $18.00 |
| Jun 12, 2024 | Roth MKM | Buy | Maintains | $N/A | |
| Aug 14, 2023 | Roth MKM | Buy | Reiterates | $N/A | |
| Dec 7, 2022 | Roth Capital | Buy | Initiates | $N/A | |
| Sep 28, 2022 | Maxim Group | Buy | Initiates | $N/A | |
| Dec 1, 2021 | Roth Capital | Buy | Initiates | $N/A |
Biorestorative Therapies Inc. (BRTX) Competitors
The following stocks are similar to BioRestorative based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biorestorative Therapies Inc. (BRTX) Financial Data
Biorestorative Therapies Inc. has a market capitalization of $9.96M with a P/E ratio of -0.3x. The company generates $357,870 in trailing twelve-month revenue with a 93.4% profit margin.
Revenue growth is -7.3% quarter-over-quarter, while maintaining an operating margin of -14,612.6% and return on equity of -241.1%.
Valuation Metrics
Market Cap
$9.96M
Enterprise Value
$6.37M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
27.8x
Growth & Margins
Revenue Growth (YoY)
-7.3%
Gross Margin
+68.1%
Operating Margin
-14,612.6%
Net Margin
+93.4%
EPS Growth
-7.3%
Financial Health
Cash/Price Ratio
+36.1%
Current Ratio
2.4x
Debt/Equity
0.0x
ROE
-241.1%
ROA
-118.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biorestorative Therapies Inc. (BRTX) Business Model
About Biorestorative Therapies Inc.
What They Do
Develops advanced stem cell-based therapies.
Business Model
The company operates through three main segments: a disc and spine program targeting chronic pain with its autologous stem cell therapy BRTX-100, a metabolic program using stem cells to combat obesity, and a BioCosmeceutical platform offering aesthetic products. Revenue is generated through the clinical development and commercialization of these innovative therapies and products.
Additional Information
BRTX-100 is in Phase 2 clinical trials and has received FDA Fast Track designation, indicating the potential for expedited approval. The company focuses on proprietary protocols for collecting adult stem cells, emphasizing its commitment to addressing unmet medical needs in regenerative medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
11
CEO
Mr. Lance Alstodt
Country
United States
IPO Year
2020
Website
www.biorestorative.comBiorestorative Therapies Inc. (BRTX) Latest News & Analysis
Latest News
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
20 days ago
Quick Summary
Kaos Capital has acquired 4.9% of BioRestorative Therapies, Inc. and is seeking a meeting with the BRTX Board to discuss value-unlocking opportunities for shareholders.
Why It Matters
Kaos Capital's acquisition of 4.9% in BRTX signals potential changes in management or strategy, which could impact stock value and shareholder returns.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A Phase 2 study with 99 patients has completed treatment. The company is proceeding with Phase 3 readiness after aligning with the FDA in a Type B meeting.
Why It Matters
Completion of Phase 2 study indicates progress in drug development, increasing potential for FDA approval and future revenue, positively impacting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.19 per share, better than the estimated loss of $0.30 and an improvement from a $0.56 loss per share a year prior.
Why It Matters
BRTX's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and affecting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Biorestorative Therapies (BRTX) has received a Zacks Rank #2 (Buy) upgrade, indicating improved earnings outlook and potential for stock price growth.
Why It Matters
BRTX's upgrade to a Zacks Rank #2 signals positive earnings outlook, potentially increasing investor confidence and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Research shows that MSC-derived extracellular vesicles have unique functional properties, indicating potential for specific regenerative and aesthetic medical applications.
Why It Matters
The findings suggest potential advancements in regenerative medicine and aesthetics, indicating growth opportunities for companies in these sectors, which could influence stock valuations and investment strategies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BioRestorative Therapies reported at ISCT 2026 that 52% of patients in its Phase 2 trial of BRTX-100 showed significant improvement in pain and function, with no safety concerns noted.
Why It Matters
Positive trial results for BioRestorative's BRTX-100 indicate significant patient improvement and safety, potentially boosting investor confidence and stock value in the regenerative medicine sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BRTX Stock
What is Biorestorative Therapies Inc.'s (BRTX) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Biorestorative Therapies Inc. (BRTX) has a median price target of $8.00. The highest price target is $15.00 and the lowest is $1.00.
Is BRTX stock a good investment in 2026?
According to current analyst ratings, BRTX has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BRTX stock?
Wall Street analysts predict BRTX stock could reach $8.00 in the next 12 months. This represents a 1,946.0% increase from the current price of $0.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biorestorative Therapies Inc.'s business model?
The company operates through three main segments: a disc and spine program targeting chronic pain with its autologous stem cell therapy BRTX-100, a metabolic program using stem cells to combat obesity, and a BioCosmeceutical platform offering aesthetic products. Revenue is generated through the clinical development and commercialization of these innovative therapies and products.
What is the highest forecasted price for BRTX Biorestorative Therapies Inc.?
The highest price target for BRTX is $15.00 from at , which represents a 3,736.3% increase from the current price of $0.39.
What is the lowest forecasted price for BRTX Biorestorative Therapies Inc.?
The lowest price target for BRTX is $1.00 from at , which represents a 155.8% increase from the current price of $0.39.
What is the overall BRTX consensus from analysts for Biorestorative Therapies Inc.?
The overall analyst consensus for BRTX is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are BRTX stock price projections?
Stock price projections, including those for Biorestorative Therapies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 11:39 AM UTC